2results about How to "Enhanced lethality" patented technology

The invention discloses a pharmaceutical composition for enhancing the killing power of CIK cells to tumor cells and application, and belongs to the technical field of biological medicine. The pharmaceutical composition is composed of a PD-1 monoclonal antibody and a protein phosphatase PP2A inhibitor, the PD-1 monoclonal antibody is Pembrolizumab, the protein phosphatase PP2A inhibitor is LB100, and the mass ratio of the PD-1 monoclonal antibody to the protein phosphatase PP2A inhibitor is (100-10): 1. Through combined use of the PD-1 monoclonal antibody and the protein phosphatase PP2A inhibitor LB100, by adjusting related signal channels in the CIK cells, immunosuppression of tumor cells on the CIK cells is relieved, the killing activity of the CIK cells on the tumor cells is remarkably improved, more powerful immune cell support is provided for tumor treatment, and good clinical application prospects are achieved.

The application discloses application of a retinoid analogue ZSH-512 in preparation of a liver cancer immunotherapy drug. Cell and animal model experiments show that the compound ZSH-512 can regulate an immune microenvironment of hepatocellular carcinoma, increase drug efficacy of an immune checkpoint inhibitor such as an anti-PD-1 antibody, and also improve anti-tumor efficacy of the ZSH-512 itself, so that a synergistic anti-tumor effect is achieved, the defect that liver cancer is not sensitive to single immunotherapy is overcome, and the ZSH-512 has a clinical development and application prospect.